

**Medicaid Preferred Drug List (PDL) Program:
Phase I PDL Annual Review and Review of New Drugs & New Drug Classes
Pharmacy and Therapeutics Committee Meeting
Wednesday, October 31, 2005
9:00 a.m., DMAS Board Room
DRAFT AGENDA**

- **Welcome and Introductions** **Patrick W. Finnerty, Director**

- **Comments from the Secretary of Health and Human Resources** **The Honorable Jane H. Woods,
Secretary of Health and Human Resources**

- **Comments from the Chairperson** **Randy Axelrod, M.D., Chairman**

- **Acceptance of Minutes** **P&T Committee Members**
From June 8, 2005 and August 31, 2005 P&T Meetings

- **Drug Class Discussions** **P&T Committee Members**

Review of New Drugs in PDL Classes

- Factive[®] – Quinolones
- Zmax[™] – Macrolides
- Clarithromycin (Generic Biaxin[®])-Macrolides
- Actonel[®] with Calcium CO-PACK-Bisphosphonates

Phase I PDL Annual Review

- HMG CoA Reductase Inhibitors (Statins)
- Cox-2 Inhibitors
- Proton Pump Inhibitors (PPIs)
- Angiotensin Receptor Blockers (ARBs)
(formerly named Angiotensin Receptor Antagonists)
- Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
- Inhaled Corticosteroids
- Nasal Steroids
- Beta Adrenergics
- COPD- Anticholinergics
(formerly included with Beta Adrenergics)
- Beta Blockers
- Calcium Channel Blockers
- H2 Antagonists
- Second Generation Antihistamines (LSAs)
- Benzodiazepine Sedative Hypnotics
(formerly included with Sedative Hypnotics)
- Other Sedative Hypnotics
(formerly included with Sedative Hypnotics)

- **Confidential Meeting** **Confidential Meeting for
P&T Committee Members, DMAS,
and FHSC Pursuant to 42 U.S.C. §
1396r-8 to discuss pricing
information**

- **Criteria Discussion of New Drugs** **Randy Axelrod, M.D., Chairman
P&T Committee Members**

- **Criteria Discussions for Phase I PDL Drug Classes** **Randy Axelrod, M.D., Chairman
P&T Committee Members**

- **Criteria Discussions for New Drug Classes** **Randy Axelrod, M.D., Chairman
P&T Committee Members**
 - Electrolyte Depleters
 - Urinary Tract Antispasmodics
 - Topical Immunomodulators
 - Lipotropics Non-Statins: Fibric Acid
 - Lipotropics Non-Statins: Niacin Derivatives
 - *Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
 - *Phosphodiesterase 5 Inhibitor for Pulmonary Arterial Hypertension

- **Next Meeting – TBD** **Randy Axelrod, M.D., Chairman**

**Criteria discussions will be held for these classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions*

Oral presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on ***only*** the drug classes subject to annual review and specific new drugs that are listed on the Agenda. All presentations for the annual review of Phase I PDL drug classes and new drugs in Phase II & III drug classes must be newly published (October 2004 - present), clinical in nature and based on scientific material. No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

If you are interested in providing specific clinical drug information, please submit an outline of discussion points, clinical references within the stated guidelines above, your written request to speak, and the name of the presenter. Please send information to pdlinput@dmass.virginia.gov by COB Wednesday, October 5, 2005.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmass.virginia.gov by COB Wednesday, October 5, 2005.